Theravance Biopharma Inc. (NASDAQ:TBPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The firm currently has a $35.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research’s price target indicates a potential upside of 12.43% from the company’s current price. According […]
